Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: implications for chemotherapeutic options and survival.

O F Bathe, D Franceschi, A S Livingstone, F L Moffat, E Tian, B Ardalan
{"title":"Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: implications for chemotherapeutic options and survival.","authors":"O F Bathe,&nbsp;D Franceschi,&nbsp;A S Livingstone,&nbsp;F L Moffat,&nbsp;E Tian,&nbsp;B Ardalan","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To determine the association of intratumoral thymidylate synthase (TS) gene expression with resistance to fluoropyrimidines and to study the association of TS gene expression with outcome in patients with liver metastases from colorectal cancer.</p><p><strong>Methods: </strong>Intratumoral TS gene expression was measured by reverse transcriptase and polymerase chain reaction in 33 patients with liver metastases from colorectal carcinoma. Fifteen patients underwent resection, and 18 were treated with chemotherapy only. Patients with high levels of TS gene expression were compared to those with low levels of TS gene expression.</p><p><strong>Results: </strong>All patients with a high level of TS gene expression were nonresponders to fluoropyrimidine chemotherapy. Median survival in patients with unresectable disease was shorter in those who had high levels of TS gene expression (7 months vs 15 months, P = 0.02). After hepatic resection, median disease-free interval was shorter in patients with high levels of TS gene expression (5 months vs 18 months; P = 0.004). Similarly, survival was shorter after resection in those with high TS gene expression (17 months vs 43 months, P = 0.0002).</p><p><strong>Discussion: </strong>Increased TS gene expression is associated with a poor outcome in patients with liver metastases from colorectal carcinoma, whether resected or treated by chemotherapy only. This is related in part to reduced responsiveness to chemotherapeutic agents, but it also reflects inherently more aggressive behavior of metastases.</p>","PeriodicalId":79462,"journal":{"name":"The cancer journal from Scientific American","volume":"5 1","pages":"34-40"},"PeriodicalIF":0.0000,"publicationDate":"1999-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The cancer journal from Scientific American","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: To determine the association of intratumoral thymidylate synthase (TS) gene expression with resistance to fluoropyrimidines and to study the association of TS gene expression with outcome in patients with liver metastases from colorectal cancer.

Methods: Intratumoral TS gene expression was measured by reverse transcriptase and polymerase chain reaction in 33 patients with liver metastases from colorectal carcinoma. Fifteen patients underwent resection, and 18 were treated with chemotherapy only. Patients with high levels of TS gene expression were compared to those with low levels of TS gene expression.

Results: All patients with a high level of TS gene expression were nonresponders to fluoropyrimidine chemotherapy. Median survival in patients with unresectable disease was shorter in those who had high levels of TS gene expression (7 months vs 15 months, P = 0.02). After hepatic resection, median disease-free interval was shorter in patients with high levels of TS gene expression (5 months vs 18 months; P = 0.004). Similarly, survival was shorter after resection in those with high TS gene expression (17 months vs 43 months, P = 0.0002).

Discussion: Increased TS gene expression is associated with a poor outcome in patients with liver metastases from colorectal carcinoma, whether resected or treated by chemotherapy only. This is related in part to reduced responsiveness to chemotherapeutic agents, but it also reflects inherently more aggressive behavior of metastases.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
结直肠癌肝转移中胸腺苷酸合成酶基因表达的增加:对化疗选择和生存的影响。
目的:探讨结直肠癌肝转移患者肿瘤内胸腺苷酸合成酶(TS)基因表达与氟嘧啶耐药性的关系,并探讨TS基因表达与预后的关系。方法:采用逆转录酶和聚合酶链反应法检测33例结直肠癌肝转移患者瘤内TS基因的表达。15例患者接受了手术切除,18例仅接受化疗。将TS基因表达水平高的患者与TS基因表达水平低的患者进行比较。结果:所有TS基因高表达的患者对氟嘧啶化疗无反应。具有高水平TS基因表达的不可切除疾病患者的中位生存期较短(7个月vs 15个月,P = 0.02)。肝切除术后,TS基因高表达患者的中位无病间期较短(5个月vs 18个月;P = 0.004)。同样,TS基因高表达的患者术后生存期较短(17个月vs 43个月,P = 0.0002)。讨论:TS基因表达升高与结直肠癌肝转移患者预后不良相关,无论是切除还是仅接受化疗。这部分与对化疗药物的反应性降低有关,但它也反映了转移性更强的固有行为。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: a mechanism of immune escape. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. The role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group program. Overview of interleukin-2 inhalation therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1